Download PDF

1. Company Snapshot

1.a. Company Description

BIMI International Medical Inc., together with its subsidiaries, engages in the retail and wholesale distribution of medical devices, and pharmaceutical and other healthcare products in the People's Republic of China.The company operates in four segments: Wholesale Pharmaceuticals, Wholesale Medical Devices, Medical Services, and Retail Pharmacies.It distributes Stryker spinal products, Olympus endoscopes, imported imaging products, and diagnostic imaging equipment to drug stores, private clinics, pharmaceutical dealers, and hospitals in the Southwest region of the People's Republic of China.


The company also distributes generic drugs, Chinese herbal medicine, biochemical drugs, raw ingredients for pharmaceutical products, antibiotics, cardiovascular drugs, and anti-obesity medicines.In addition, it offers prescription and over-the-counter drugs, nutritional supplements, health foods, sundry products, traditional Chinese medicines, personal and family care products, medical devices, and miscellaneous items under the Lijiantang Pharmacy brand name.Further, the company provides medical services in the hospitals, as well as IT research and development services.


It sells its medicine and other healthcare products to customers through its directly owned stores.The company was formerly known as BOQI International Medical Inc.and changed its name to BIMI International Medical Inc.


in June 2021.BIMI International Medical Inc.was incorporated in 2000 and is based in Chongqing, the People's Republic of China.

Show Full description

1.b. Last Insights on BIMI

BIMI International Medical Inc.'s recent stock performance was negatively driven by the delisting of its securities from the Nasdaq Stock Market, effective January 10, 2025. The company's common stock was suspended on August 22, 2024, and has not traded since. This development has significant implications for the company's liquidity and access to capital markets. The lack of trading activity and delisting may also lead to a decrease in investor confidence and a reduction in the company's market value.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Delisting of Securities of BIMI International Medical Inc.; The Dixie Group, Inc.; Clover Leaf Capital Corp.; Focus Impact BH3 Acquisition Company; Forza X1, Inc.; Vertex Energy, Inc; Slam Corp.; and HHG Capital Corporation from The Nasdaq Stock Market

Jan -10

Source: globenewswire.com

Card image cap

BIMI Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq

Apr -23

Source: globenewswire.com

Card image cap

BIMI Announces Results of 2023 Annual General Meeting of Stockholders

Jan -03

Source: globenewswire.com

Card image cap

BIMI International Medical Inc. Announces Third Quarter 2023 Financial Results

Dec -19

Source: globenewswire.com

Card image cap

BIMI Announces Buyback of Warrants

Nov -28

Source: globenewswire.com

Card image cap

BIMI Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Nov -27

Source: globenewswire.com

Card image cap

BIMI International Medical Inc. Announces Second Quarter 2023 Financial Results

Nov -27

Source: globenewswire.com

Card image cap

BIMI Announces Subsidiary Phenix Bio Inc.'s New Product Launch

Nov -08

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.18%)

6. Segments

Drugs

Expected Growth: 8.5%

Growing demand for pharmaceutical products, increasing prevalence of chronic diseases, and expanding distribution channels drive the growth of BIMI International Medical Inc.'s drug segment.

Medical Devices

Expected Growth: 7.8%

Growing demand for innovative medical devices, increasing healthcare expenditure, and an aging population drive the growth of BIMI International Medical Inc.'s medical devices segment, offering high-quality products for diagnosis, treatment, and patient care.

Retail Pharmacy

Expected Growth: 7.4%

Increasing demand for convenient healthcare services, aging population, and growing need for preventive care drive growth in retail pharmacy market.

7. Detailed Products

Medical Imaging Equipment

State-of-the-art medical imaging equipment for hospitals and clinics, including MRI, CT, and X-ray machines.

Radiation Therapy Systems

Advanced radiation therapy systems for cancer treatment, including linear accelerators and brachytherapy systems.

Medical Software Solutions

Comprehensive software solutions for medical imaging, radiation therapy, and healthcare information systems.

Medical Imaging Consumables

High-quality medical imaging consumables, including MRI and CT contrast agents, and radiopharmaceuticals.

Radiation Detection and Monitoring Systems

Advanced radiation detection and monitoring systems for nuclear medicine, radiation therapy, and industrial applications.

Medical Education and Training

Comprehensive education and training programs for medical professionals, including workshops, conferences, and online courses.

8. BIMI International Medical Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for BIMI International Medical Inc. is medium due to the availability of alternative medical services and products.

Bargaining Power Of Customers

The bargaining power of customers is high due to the high demand for medical services and products, giving customers the power to negotiate prices and services.

Bargaining Power Of Suppliers

The bargaining power of suppliers is low due to the availability of multiple suppliers and the company's ability to negotiate prices and terms.

Threat Of New Entrants

The threat of new entrants is medium due to the moderate barriers to entry in the medical industry, including regulatory requirements and capital investments.

Intensity Of Rivalry

The intensity of rivalry is high due to the competitive nature of the medical industry, with many established players competing for market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 57.41%
Debt Cost 12.61%
Equity Weight 42.59%
Equity Cost 12.61%
WACC 12.61%
Leverage 134.78%

11. Quality Control: BIMI International Medical Inc. passed 1 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
LifeMD

A-Score: 4.9/10

Value: 6.2

Growth: 7.3

Quality: 6.4

Yield: 0.0

Momentum: 8.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Meihua Medical

A-Score: 4.6/10

Value: 10.0

Growth: 4.9

Quality: 7.5

Yield: 0.0

Momentum: 1.5

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
NEUCA

A-Score: 4.1/10

Value: 4.7

Growth: 3.9

Quality: 3.9

Yield: 3.1

Momentum: 1.5

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
BioNexus Gene Lab

A-Score: 4.1/10

Value: 8.0

Growth: 2.8

Quality: 4.8

Yield: 0.0

Momentum: 8.5

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
BIMI International Medical

A-Score: 3.6/10

Value: 10.0

Growth: 3.8

Quality: 2.6

Yield: 0.0

Momentum: 5.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Qilian International Holding

A-Score: 3.3/10

Value: 7.5

Growth: 3.0

Quality: 3.4

Yield: 0.0

Momentum: 6.0

Volatility: 0.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.0$

Current Price

0.0$

Potential

-0.00%

Expected Cash-Flows